BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33580628)

  • 21. Survival benefits of postoperative radiotherapy in patients with cT
    Yang J; Zhao J; Chang H; Yan L; Zhang J; Liu H; Ning P
    BMC Womens Health; 2024 Jun; 24(1):324. PubMed ID: 38834997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.
    Zang J; Li C; Xu M; Xu W; Kang X; Wang J; Luo S; Shi M
    Sci Rep; 2018 Sep; 8(1):13318. PubMed ID: 30190563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of the Albumin-to-Alkaline Phosphatase Ratio before Chemoradiotherapy in Patients with Nonmetastatic Nasopharyngeal Carcinoma.
    Yang L; Gao J; Zhou Y; Tao Z; He J; Yang J; Wang R; Zhang Y; Huang Y; Zhou L; Sun B
    Chemotherapy; 2021; 66(1-2):40-46. PubMed ID: 33601377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined radiotherapy and chemotherapy versus radiotherapy alone in elderly patients with nasopharyngeal carcinoma: A SEER population-based study.
    Lu Y; Hua J; Yan F; Jiang C; Piao Y; Ye Z; Fu Z; Jiang H; Wang F; Jiang Y
    Medicine (Baltimore); 2021 Jul; 100(29):e26629. PubMed ID: 34398019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after neoadjuvant chemotherapy followed by surgery - A propensity score matching study of the Surveillance, Epidemiology, and End Results database.
    Bao Y; Yang X; Men Y; Kang J; Sun X; Zhao M; Sun S; Yuan M; Ma Z; Hui Z
    Thorac Cancer; 2022 Feb; 13(3):404-411. PubMed ID: 34907665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The stage-specific roles of radiotherapy and chemotherapy in nodular lymphocyte predominant Hodgkin lymphoma patients: a propensity score-matched analysis of the SEER database.
    Wang S; Jia M; Han J; Zhang R; Huang K; Qiao Y; Chen P; Fu Z
    Cancer Med; 2021 Jan; 10(2):540-551. PubMed ID: 33249743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
    Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The detrimental effects of radiotherapy interruption on local control after concurrent chemoradiotherapy for advanced T-stage nasopharyngeal carcinoma: an observational, prospective analysis.
    Yao JJ; Jin YN; Wang SY; Zhang F; Zhou GQ; Zhang WJ; Zhi-Bin ; Cheng ; Ma J; Qi ZY; Sun Y
    BMC Cancer; 2018 Jul; 18(1):740. PubMed ID: 30012115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
    Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J
    Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maximal lymph nodal diameter on N stage of nasopharyngeal carcinoma.
    Huang ST; Qu S; Li L; Chen KH; Zhu XD; Pan XB
    Medicine (Baltimore); 2021 Jul; 100(26):e26543. PubMed ID: 34190192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival without adjuvant chemotherapy for selected patients with stage II and III nasopharyngeal carcinoma after concurrent chemoradiotherapy alone.
    Wu JS; Tsai YC; Jian JJ; Chen HH; Horng CF; Cheng SH
    Head Neck; 2018 Sep; 40(9):2070-2077. PubMed ID: 29756398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial.
    Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M
    Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies.
    Yang G; Huang J; Sun J; Wang L
    Cancer Med; 2023 Oct; 12(19):19523-19529. PubMed ID: 37724570
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
    Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.